Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.910
+0.020 (1.06%)
At close: Sep 12, 2025, 4:00 PM EDT
1.900
-0.010 (-0.52%)
After-hours: Sep 12, 2025, 6:16 PM EDT

Citius Oncology Statistics

Total Valuation

Citius Oncology has a market cap or net worth of $159.51 million. The enterprise value is $163.31 million.

Market Cap159.51M
Enterprise Value 163.31M

Important Dates

The last earnings date was Tuesday, August 12, 2025, after market close.

Earnings Date Aug 12, 2025
Ex-Dividend Date n/a

Share Statistics

Citius Oncology has 83.51 million shares outstanding. The number of shares has increased by 5.32% in one year.

Current Share Class 83.51M
Shares Outstanding 83.51M
Shares Change (YoY) +5.32%
Shares Change (QoQ) n/a
Owned by Insiders (%) 0.03%
Owned by Institutions (%) 0.27%
Float 17.44M

Valuation Ratios

PE Ratio n/a
Forward PE 95.50
PS Ratio n/a
Forward PS n/a
PB Ratio 4.22
P/TBV Ratio 4.92
P/FCF Ratio n/a
P/OCF Ratio 1,262.42
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.35, with a Debt / Equity ratio of 0.12.

Current Ratio 0.35
Quick Ratio n/a
Debt / Equity 0.12
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -158.50

Financial Efficiency

Return on equity (ROE) is -107.54% and return on invested capital (ROIC) is -59.84%.

Return on Equity (ROE) -107.54%
Return on Assets (ROA) -22.47%
Return on Invested Capital (ROIC) -59.84%
Return on Capital Employed (ROCE) -65.81%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, Citius Oncology has paid $936,720 in taxes.

Income Tax 936,720
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +13.02% in the last 52 weeks. The beta is 3.01, so Citius Oncology's price volatility has been higher than the market average.

Beta (5Y) 3.01
52-Week Price Change +13.02%
50-Day Moving Average 2.12
200-Day Moving Average 1.41
Relative Strength Index (RSI) 48.99
Average Volume (20 Days) 212,436

Short Selling Information

The latest short interest is 303,360, so 0.36% of the outstanding shares have been sold short.

Short Interest 303,360
Short Previous Month 236,767
Short % of Shares Out 0.36%
Short % of Float 1.74%
Short Ratio (days to cover) 0.84

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -25.48M
Pretax Income n/a
Net Income -26.58M
EBITDA n/a
EBIT -25.48M
Earnings Per Share (EPS) -$0.37
Full Income Statement

Balance Sheet

The company has $112 in cash and $3.80 million in debt, giving a net cash position of -$3.80 million or -$0.05 per share.

Cash & Cash Equivalents 112
Total Debt 3.80M
Net Cash -3.80M
Net Cash Per Share -$0.05
Equity (Book Value) 32.40M
Book Value Per Share 0.45
Working Capital -34.68M
Full Balance Sheet

Cash Flow

Operating Cash Flow 126,353
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Citius Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -5.32%
Shareholder Yield -5.32%
Earnings Yield -16.66%
FCF Yield n/a

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus Hold
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 3